blindness with glp 1 GLP-1 Agonists—commonly used for weight loss and diabetes—are now being linked to serious eye health concerns, including an increased risk of a condition called NAION, which can cause irreversible blindness. GLP-1 GLP-1 Receptor Agonists and vision

References Khavinson VKh et al., Bull Exp Biol Med 2003 telomerase in fibroblasts Anisimov VN et al., Biogerontology 2003 lifespan in CBA mice Korkushko OV et al., Bull Exp Biol Med 2007 elderly cohort outcomes St Petersburg Institute of Bioregulation and Gerontology research index See also our editorial coverage at PeptideAuthority.co.uk for related research dossiers

Naturopathic Initial Assessment required prior to booking

6 Conclusion The impact of poor outcomes in preterm infants has prompted the exploration and optimization of new treatment regimens

Why the benefits of GLP-1 medications outweigh the risks GLP-1 drugs like Ozempic and Mounjaro offer life-changing health outcomes: 1020% weight loss Better control of type 2 diabetes Lower blood pressure and cholesterol Reduced risk of heart disease, stroke, and kidney damage For most patients, these benefits outweigh the very low and uncertain risk of pancreatitis